EBC is a network of key players in the “Brain Area”, with a membership encompassing scientific societies, patient organisations, professional societies and industry partners.
8 12-2022

Registration now open for the launch event of the RETHINKING Alzheimer’s disease White Paper

2023-01-10T12:03:16+00:0008-12-2022|News|

Registration is now open for the launch event of the RETHINKING Alzheimer's disease White Paper, taking place virtually on 24 January 2023 at 12:30 – 14:00. The European Brain Council (EBC), in collaboration with the European Federation of Pharmaceutical Industries and Associations (EFPIA), will present its White Paper “RETHINKING Alzheimer’s disease: Detection and diagnosis“. This paper [...]

24 11-2022

Save the date for the launch event of the RETHINKING Alzheimer’s disease White Paper!

2023-01-10T13:12:36+00:0024-11-2022|News|

The launch event of the RETHINKING Alzheimer's disease White Paper, calling for change in Alzheimer's care, will take place virtually on 24 January 2023 at 12:30 - 14:00. About Alzheimer's disease Alzheimer’s disease (AD) is a neurodegenerative disease that progresses in stages, beginning with a long silent phase before symptoms occur. It is the underlying cause [...]

24 05-2022

RETHINKING Alzheimer’s disease project, calling for change in Alzheimer’s care, kicks off!

2022-05-24T07:55:53+00:0024-05-2022|News|

Through RETHINKING Alzheimer’s disease (AD), the European Brain Council (EBC) and the European Federation of Pharmaceutical Industries and Associations (EFPIA) are joining forces with the ambition of improving Alzheimer’s disease care pathway and the lives of people living with it. Officially launched on 29 April 2022, the project kicked off its operational activities with [...]

5 07-2021

EBC supports the need to prioritise the rapidly growing challenge of Alzheimer’s disease

2021-07-07T11:46:51+00:0005-07-2021|News|

Alzheimer’s disease (AD) is a neurodegenerative disease that progresses in stages, beginning with a long silent phase before symptoms occur, and the underlying cause in 70% of people with dementia. Dementia, which is not a specific disease but an overall term that describes a group of symptoms, is characterized by a decline in memory, thinking, [...]

3 04-2019

EBC-endorsed “Alzheimer’s Policy toolkit for Members of the European Parliament” released

2019-04-03T08:12:29+00:0003-04-2019|News|

Alzheimer’s disease (AD) – the most common cause of dementia – is one of the most significant medical and societal challenges of our time. It does not discriminate and affects everyone, across all generations – from the people who develop the condition, to the families that care for them and the taxpayers who fund health [...]

3 10-2017

EBC at 27th Alzheimer Europe Conference

2017-10-03T12:03:42+00:0003-10-2017|News|

EBC is in Berlin this week for the 27th Alzheimer Europe Conference, focusing this year on the theme "care today, cure tomorrow". In partnership with MSD we are present at the exhibition and will hold a special symposium on the 4th October during lunch (beginning 12:45): Early intervention in Alzheimer’s disease: For a new understanding of [...]

Go to Top